ライフサイエンスコーパス: dose-dense

1 the hospitalization rates ranged from 6.2% (dose-dense AC + P) to 10.0% (TAC), and those who receive

2 than age 65 years, all regimens (aside from dose-dense AC + P) were associated with a higher risk of

3 ide (C), doxorubicin (A) and C, TAC, AC + T, dose-dense AC + paclitaxel (P) or AC + weekly P.

4 r toxicity and dose-delivery were similar to dose-dense AC --> paclitaxel in Cancer and Leukemia Grou

5 Dose-dense AC followed by P/T followed by T is feasible

6 We conducted a pilot study of dose-dense AC followed by PT plus lapatinib (PTL) follow

7 Dose-dense AC followed by PTL and then followed by TL wa

8 Tipifarnib may be safely combined with dose-dense AC using a dose and schedule that significant

9 Dose-dense AC with or without concurrent bevacizumab is

10 e pCR rate after four cycles of preoperative dose-dense AC.

11 Objective: To determine whether tailored dose-dense adjuvant chemotherapy improves the outcomes o

12 prove outcomes is unknown, as is the role of dose-dense adjuvant chemotherapy.

13 cycles of leukocyte nadir-based tailored and dose-dense adjuvant epirubicin and cyclophosphamide ever

14 Salvage chemotherapy regimens integrating dose dense and vertical dose intensification strategies

15 were enrolled; 42 were randomly assigned to dose-dense and 43 to metronomic temozolomide.

16 d by HDC with AHPCS or to receive sequential dose-dense and dose-escalated chemotherapy with doxorubi

17 e feasibility and efficacy of giving uniform dose-dense and dose-intense cytoreductive chemotherapy a

18 s the use up-front of all active agents in a dose-dense and dose-intense fashion, as practiced in Tot

19 a comprehensive 2-step protocol encompassing dose-dense and dose-intense second-line chemotherapy, fo

20 Both dose-dense and metronomic temozolomide regimens were wel

21 erging evidence that other therapies such as dose-dense and metronomic temozolomide regimens, targete

22 To evaluate the efficacy of a dose-dense approach consolidated by up-front high-dose c

23 Randomized trials testing the dose-dense approach have been completed but not yet repo

24 progression-free survival (6.6 months in the dose-dense arm and 5.0 months in the metronomic arm).

25 The 1-year survival rate was 80% for the dose-dense arm and 69% for the metronomic arm; median OS

26 There was greater deterioration in the dose-dense arm from baseline to cycle 4 in the Global He

27 bserved in patients randomly assigned to the dose-dense arm.

28 and Drug Administration and the benefits of dose-dense breast cancer chemotherapy, especially for ho

29 likely a result of the reported benefits of dose-dense chemotherapy and the ease of pegfilgrastim ad

30 isk early breast cancer, the use of tailored dose-dense chemotherapy compared with standard adjuvant

31 addition of recommendations against routine dose-dense chemotherapy in lymphoma and in favor of high

32 r women with HR-positive tumors treated with dose-dense chemotherapy is estimated to be $38.8 million

33 Dose-dense chemotherapy is predicted to be a superior tr

34 were randomly assigned 1:1 to two different dose-dense chemotherapy regimens and 2:1 to ibandronate

35 ing a subset of trials comparing intensified/dose-dense chemotherapy versus standard-dose regimens (D

36 rly HR-positive patients do not benefit from dose-dense chemotherapy, limiting pegfilgrastim use woul

37 High treatment efficacy is achieved using dose-dense chemotherapy.

38 h high-risk early breast cancer who received dose-dense chemotherapy.

39 e estimated for patients who were undergoing dose-dense chemotherapy.

40 length less than 21 days as having received dose-dense chemotherapy.

41 after 2002 and estimated US expenditures for dose-dense chemotherapy.

42 l doses) and 55 received a dose-intensified, dose-dense concomitant regimen of epirubicin + cyclophos

43 sequential cyclophosphamide administration, dose-dense consolidation, late intensification, CNS prop

44 Dose-dense (dd) AC followed by paclitaxel (P) is superio

45 Dose-dense (dd) doxorubicin and cyclophosphamide (AC) fo

46 Dose-dense (DD) regimens of combination chemotherapy may

47 Dose-dense (DD) temozolomide results in prolonged deplet

48 ery 2 weeks followed by 4 cycles of tailored dose-dense docetaxel every 2 weeks, or to standard-inter

49 rogenitor cell support (AHPCS) with a modern dose-dense dose-escalated (nonstandard) regimen includin

50 vidence that transplantation was superior to dose-dense dose-escalated therapy.

51 Dose-dense doxorubicin and cyclophosphamide (AC) followe

52 asibility trial testing this hypothesis with dose-dense doxorubicin and cyclophosphamide (ddAC).

53 ntial CT consisting of either four cycles of dose-dense doxorubicin at 60 mg/m(2) every 2 weeks follo

54 She received neoadjuvant dose-dense doxorubicin, cyclophosphamide, and paclitaxel

55 Therefore, we studied dose-dense doxorubicin, paclitaxel, and cyclophosphamide

56 hamide) to (1) enhance treatment efficacy by dose-dense drug delivery and (2) reduce risk of long-ter

57 Efficient induction of early response by dose-dense drug delivery supported an early-response-ada

58 pothesized that 3 months of paclitaxel after dose-dense EC (EC/T) would be superior to CEF or AC/T.

59 rly to detect any difference between CEF and dose-dense EC/T.

60 More cells were killed by PTX dose-dense-equi than with PTX conventional, but with the

61 Dose-dense, every-2-week adjuvant chemotherapy using dox

62 fter 2003, all treatment was administered in dose-dense fashion.

63 17 randomized patients (1006 in the tailored dose-dense group and 1011 in the control group; median [

64 FS events were reported, 118 in the tailored dose-dense group and 151 in the control group (HR, 0.79;

65 s required in six (6%) patients in the Unfav-dose-dense group and 16 (16%) in the Unfav-BEP group.

66 ects occurred in 527 (52.6%) in the tailored dose-dense group and 366 (36.6%) in the control group.

67 ine; 105 were randomly assigned to the Unfav-dose-dense group and 98 to the Unfav-BEP group.

68 cycle of chemotherapy; 1001 in the tailored dose-dense group and 999 in the control group).

69 nd haematotoxic events occurred in the Unfav-dose-dense group compared with in the Unfav-BEP group; t

70 The tailored dose-dense group had significantly better EFS than the c

71 survival was 59% (95% CI 49-68) in the Unfav-dose-dense group versus 48% (38-59) in the Unfav-BEP gro

72 av-BEP group) or a dose-dense regimen (Unfav-dose-dense group), consisting of intravenous paclitaxel

73 c effects were more frequent in the tailored dose-dense group.

74 In the DDP/PTX dose-dense-high scheme, both cell death and regrowth imp

75 Therefore, dose-dense induction and HDT/ASCT are a rational up-fron

76 Dose-dense induction and up-front consolidation with aut

77 Dose-dense induction followed by HDT/ASCT was well toler

78 n advanced urothelial cancer, treatment with dose-dense methotrexate, vinblastine, doxorubicin, and c

79 ily, 5 days per week for up to 6.5 weeks) or dose-dense oral temozolomide (75 mg/m(2) once daily for

80 the safety and feasibility of the sequential dose-dense plan.

81 The results support the option for dose-dense PTX chemotherapy with active single doses, sh

82 to receive either BEP (Unfav-BEP group) or a dose-dense regimen (Unfav-dose-dense group), consisting

83 The dose-dense regimen appears promising, with 1-year surviv

84 ABVE-PC is a dose-dense regimen that provides outstanding event-free

85 Four-year DFS was 82% for the dose-dense regimens and 75% for the others.

86 Dose-dense regimens should only be used within an approp

87 Dose-dense regimens that require CSFs should only be use

88 s less frequent in patients who received the dose-dense regimens.

89 tine, cyclophosphamide, and doxorubicin with dose-dense rituximab (SC-EPOCH-RR) in newly diagnosed HI

90 tional and two levels ("equi" and "high") of dose-dense schedules.

91 Dose-dense sequential adjuvant chemotherapy with doxorub

92 evaluation did not predict outcome with this dose-dense, sequential immunochemotherapy program.

93 ve-year DFS was 80% (95% CI, 76% to 85%) for dose-dense therapy and 75% (95% CI, 69% to 80%) for tran

94 d 5-year OS was 88% (95% CI, 84% to 92%) for dose-dense therapy and 84% (95% CI, 79% to 88%) for tran

95 determine the safety and feasibility of this dose-dense treatment and to estimate the disease-free an

96 ic therapy with taxanes, platinum agents, or dose-dense treatment can be safely given during pregnanc

97 Dose-dense treatment improved the primary end point, DFS

98 to evaluate differences between treatments (dose-dense v standard-dose) on NCB measures from baselin

99 phosphamide (EC) administered every 2 weeks (dose-dense) was equivalent to 6 months of CEF.

100 We proposed to determine whether dose-dense weekly paclitaxel and carboplatin would prolo

101 A dose-dense weekly schedule of paclitaxel (resulting in a